The company has historically used contract manufacturers (CMOs) for their process liquid portfolio, including water for injection (WFI), NaOH solutions, PBS, and other common salt solutions.
The company’s legacy CMO made strategic decision to deprioritize contract manufacturing and focus more on direct sales to end markets. As a result, the company begin to experience inconsistent and long lead times for critical process liquid products, resulting in end customer dissatisfaction and loss of share due to stockouts and backordered catalog MTS items.
The company needed to partner with a CMO that would commit to providing long-term service and assurance of supply.
GeminiBio worked with the company to determine the detailed specifications and requirements for a specific portfolio of made to stock (MTS) cGMP process liquids, including water for injection (WFI) and a range of salt solutions.
GeminiBio worked with the company to execute pilot batches and complete a comprehensive audit process to validate GeminiBio’s contract manufacturing service for the in-scope MTS products.
As part of the contract manufacturing agreement, GeminiBio committed to market-leading service level agreements (SLAs) to ensure the company had assurance of supply and annual volume commitments.
As a result, the company was able to provide consistent supply to their end-customers, improving customer satisfaction and market share growth.